X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (129) 129
index medicus (119) 119
hematology (91) 91
middle aged (81) 81
life sciences (77) 77
male (77) 77
female (74) 74
cancer (69) 69
aged (68) 68
adult (61) 61
oncology (57) 57
transplantation (43) 43
treatment outcome (40) 40
[sdv.can]life sciences [q-bio]/cancer (37) 37
mantle cell lymphoma (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
lymphomas (31) 31
[ sdv.can ] life sciences [q-bio]/cancer (30) 30
chemotherapy (30) 30
retrospective studies (28) 28
prognosis (26) 26
survival (26) 26
hemic and lymphatic diseases (25) 25
immunology (24) 24
lymphoma (23) 23
rituximab (23) 23
multiple myeloma (22) 22
apoptosis (21) 21
young adult (21) 21
aged, 80 and over (20) 20
analysis (20) 20
cell line, tumor (20) 20
abridged index medicus (18) 18
adolescent (18) 18
disease-free survival (18) 18
stem cells (18) 18
survival analysis (18) 18
trial (18) 18
apoptosis - drug effects (17) 17
hematology, oncology and palliative medicine (16) 16
neoplasm staging (16) 16
research (16) 16
transplantation, homologous (16) 16
hematopoietic stem cell transplantation - methods (15) 15
immune system diseases (15) 15
recurrence (15) 15
animals (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
chronic lymphocytic-leukemia (14) 14
follow-up studies (14) 14
multiple myeloma - pathology (14) 14
non-hodgkins-lymphoma (14) 14
prospective studies (14) 14
therapy (14) 14
article (13) 13
bone-marrow-transplantation (13) 13
care and treatment (13) 13
leukemia (13) 13
lymphoma, mantle-cell - drug therapy (13) 13
lymphoma, mantle-cell - therapy (13) 13
multiple-myeloma (13) 13
progression-free survival (13) 13
stem cell transplantation (13) 13
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
cyclophosphamide (12) 12
expression (12) 12
gene expression regulation, neoplastic (12) 12
remission induction (12) 12
transplantation, autologous (12) 12
antineoplastic agents - therapeutic use (11) 11
cell biology (11) 11
disease progression (11) 11
high-dose therapy (11) 11
immunochemotherapy (11) 11
medicine & public health (11) 11
multiple myeloma - drug therapy (11) 11
multiple myeloma - genetics (11) 11
multiple myeloma - metabolism (11) 11
relapse (11) 11
survival rate (11) 11
time factors (11) 11
antineoplastic agents - pharmacology (10) 10
combined modality therapy (10) 10
cyclophosphamide - administration & dosage (10) 10
follicular lymphoma (10) 10
lymphoma, mantle-cell - pathology (10) 10
proteins (10) 10
transplantation conditioning - methods (10) 10
biochemistry & molecular biology (9) 9
bortezomib (9) 9
clinical trials (9) 9
drug administration schedule (9) 9
genetic aspects (9) 9
human health and pathology (9) 9
kaplan-meier estimate (9) 9
multicenter (9) 9
non-hodgkin-lymphoma (9) 9
patients (9) 9
versus-host-disease (9) 9
allogeneic stem cell transplantation (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hematologie, ISSN 1264-7527, 05/2015, Volume 21, Issue 3, pp. 169 - 172
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 14, pp. 1486 - 1494
Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab. Given promising results... 
Life Sciences | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4158 - 4158
Abstract Background. Mantle Cell Lymphoma (MCL) drug resistance are highly dependent on B-cell-receptor signaling, Bcl-2 and the microenvironment. Ibrutinib... 
Journal Article
Leukemia, ISSN 0887-6924, 2019
The microenvironment strongly influences mantle cell lymphoma (MCL) survival, proliferation and chemoresistance. However, little is known regarding the... 
Life Sciences | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2855 - 2855
Abstract The aggressive clinical behavior of mantle cell lymphoma (MCL) and its short-term response to treatments highlight a need for novel options. The... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 310 - 310
Abstract P53 plays a pleiotropic role in cell homeostasis by regulating stress-induced adaptive responses leading to survival or cell death. Although it is... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4612 - 4612
Abstract Introduction: high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) is an effective treatment in relapsed follicular lymphoma... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS7583 - TPS7583
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 2987 - 2987
Abstract Temsirolimus has shown clinical activity in heavily pretreated patients with mantle cell lymphoma (MCL) leading to evaluate tolerability and efficacy... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 5384 - 5384
Abstract Background: Ibrutinib is a first-in-class selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK) approved for the treatment of patients... 
Journal Article
Leukemia, ISSN 0887-6924, 03/2016, Volume 30, Issue 3, pp. 761 - 764
INHIBITION | ONCOLOGY | MCL-1 | DEATH | LEUKEMIA | HEMATOLOGY | ABT-199 | ADDICTION | Recurrence | Antineoplastic Agents - chemical synthesis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | bcl-X Protein - genetics | Male | Plasma Cells - pathology | Plasma Cells - drug effects | Proto-Oncogene Proteins c-bcl-2 - metabolism | Peptides - chemical synthesis | bcl-X Protein - antagonists & inhibitors | Aged, 80 and over | Biological Assay | Female | Plasma Cells - metabolism | Antineoplastic Agents - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - chemical synthesis | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Aniline Compounds - pharmacology | Cytochromes c - secretion | Multiple Myeloma - diagnosis | Mitochondria - metabolism | Mitochondria - drug effects | Mitochondria - pathology | Multiple Myeloma - metabolism | Organ Specificity | Sulfonamides - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Peptides - pharmacology | Sulfonamides - chemical synthesis | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Multiple Myeloma - pathology | Cell Line, Tumor | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-bcl-2 - genetics | Aniline Compounds - chemical synthesis | Multiple Myeloma - genetics | Drug metabolism | Development and progression | Genetic aspects | Tumor proteins | Health aspects | Multiple myeloma | Life Sciences | Cancer | BCL-2 | BH3 profiling | BH3 mimetics | Multiple Myeloma | Apoptosis
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 1745 - 1745
Abstract Introduction: Prognosis markers available at diagnosis are needed to discriminate high-risk (HR) from low-risk (LR) mantle cell lymphoma (MCL)... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4458 - 4458
Abstract BACKGROUND: Lenalidomide exerts anti-proliferative activity on lymphoma cells, enhances T- and NK-cell function, and improves ADCC. The combination of... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 417 - 417
Abstract Despite significant improvement in the treatment of Multiple Myeloma (MM), patients still experience relapse and the disease remains incurable.... 
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2016, Volume 16, Issue 1, p. 802
AbstractBackgroundMantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in... 
Life Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Life Sciences
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.